Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non–small cell lung cancer (NSCLC).
Тэги:
#targeted_oncology #oncology #cancer